Protons represent a logical step forward as a modality for radiotherapy because it is possible to concentrate dose in the tumor region and minimize dose to normal tissue. The pencil beam emerging from a cyclotron or synchrotron needs to be expanded to a larger size to cover tumors of realistic size. Ideally, this should be accomplished by scanning the pencil beam using magnetic fields, but this is technically challenging. The simpler method is to use passive modulation, the downside of which is that neutrons are produced in the scattering foil, which results in a total body dose to the patient. Neutrons are highly effective at inducing second cancers and so, for the full potential of protons to be realized, spot scanning is essential.
PierceD. A.PrestonD. L.Radiation-related cancer risks at low doses among atomic bomb survivors. Radiat Res154, 178–186 (2000).
2.
BrennerD. J.CurtisR. E.HallE. J.Second malignancies in prostate patients after radiotherapy compared with surgery. Cancer88, 398–406 (2000).
3.
BoiceJ. D.JrEngholmG.KleinmanR. A.Radiation dose and second cancers risk in patients treated for cancer of the cervix. Radiat Res116, 3–55 (1988).
4.
NyandotoP.MuhonenT.JoensuuH.Second cancers among long-term survivors from Hodgkin's disease. Int J Radiat Oncol Biol Phys42, 373–378 (1998).
5.
FollowillD.GeisP.BoyerA.Estimates of whole-body dose equivalent produced by beam intensity modulated conformal therapy. Int J Radiat Oncol Biol Phys38, 667–672 (1997).
6.
GrayL. H.Radiation biology and cancer. In: Cellular radiation biology: A symposium considering radiation effects in the cell and possible implications for cancer therapy, p. 8–25. Baltimore: William & Wilkins (1965).
7.
RonE.Personal communication (2005).
8.
HallE. J.WuuC.Radiation-induced second cancers: The impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys56, 83–88 (2003).
9.
KryS. F.SalehpourM.FollowillD.The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys62, 1195–1203 (2005).
10.
International Commission on Radiological Protection. Recommendations. Annals of the ICRP Publication 60.Oxford, England: Pergamon Press (1990).
11.
YanX.TittU.KoehlerA. M.Measurement of neutron dose equivalent to proton therapy patients outside of the proton radiation field. Nucl Instr Meth in Phys ResA476, 476–434 (2002).
12.
HallE. J.Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys65, 1–7 (2006).
13.
GottschalkB.Neutron dose in scattered and scanned proton beams; in regard to Eric Hall (Int J Radiat Oncol Biol Phys2006;65:1–7). Int J Radiat Oncol Biol Phys66, 1594 (2006).
14.
PaganettiH.BortfeldT.DelaneyT. F.Neutron dose in proton radiation therapy: In regard to Eric Hall (Int J Radiat Oncol Biol Phys2006;65:1–7). Int J Radiat Oncol Biol Phys66, 1594 (2006).
15.
NolteR.MuhlbradtK.-H.MeuldersJ. P.StephanG.HaneyM.SchmidE.RBE of quasi-monoenergetic 60 MeV neutron radiation for induction of dicentric chromosomes in human lymphocytes. Radiat Environ Biophys44, 201–209 (2005).
16.
SchneiderU.AgosteoS.PedroniE.Secondary neutron dose during proton therapy using spot scanning. Int J Radiat Oncol Biol Phys53, 244–251 (2002).
17.
MacDougallR. H.KerrG. R.DuncanW.Incidence of sarcoma in patients treated with fast neutrons. Int J Radiat Oncol Biol Phys66, 842–844 (2006).
